Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase NA 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Large B-Cell, Diffuse 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Solid Tumors 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Extensive Stage Small Cell Lung Cancer 1 Cardiotoxicity 1 Burkitt Lymphoma 1

Interventions

pembrolizumab 92 Nivolumab 56 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Specimen Handling 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × oblimersen × Clear all

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡